Tacrolimus filed in Japan for wider myasthenia gravis use
This article was originally published in Scrip
Executive Summary
Astellashas made a Japanese submission to extend the use of its immunosuppressant Prograf (tacrolimus) in myasthenia gravis (MG) patients. The product was approved in 2000 for post-thymectomy MG patients in whom steroids are ineffective or inappropriate, and the new filing seeks clearance for all types of MG. The autoimmune disorder is characterised by muscle weakness from the disruption of neuromuscular transmission, and tacrolimus acts to suppress the production of lymphocyte-mediated cytokines and anti-acetylcholine receptor antibodies.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.